Methods: In vivo efficacy was evaluated in various CD4 + T cell-mediated disease models ... gradient after removing hepatocytes by centrifugation. Cells were stained and analyzed by flow cytometry.

AT&T maintains its full-year outlook of free cash flow of over $16 billion and sees around $2.8 billion or more for the first quarter. This aligns with or exceeds first-quarter 2024 levels ...

Scientists have supercharged CAR-T therapy, making it more powerful against elusive cancer cells that usually escape detection. This innovation, called ALA-CART, helps the immune system better ...